Videos

Angela Livingood, PharmD, MHA, BCGP, CPHQ, diversion specialist at Novant Health, discusses what drug diversion is and why it is important for pharmacists to be aware of it.

Brooke Looney, PharmD, certified specialty pharmacist in the Oncology Clinic at Vanderbilt Specialty Pharmacy, discusses medication changes and adverse events for patients starting encorafenib and binimetinib.

Nicholas Robert, MD, chief medical officer at Ontada, discussed disparities in biomarker testing and how they are being addressed.

Kayla Cierniak, PharmD, MS, BCPS, FISMP, medication safety officer in oncology at Seidman Cancer Center discusses the Bar Code Medication Administration and some challenges the initiative faced.

Arpit Mehta, PharmD, MPh, MHA, director of Pharmacy at Allegheny General Hospital, discusses innovations in health-system patient care models to improve patient outcomes.

Katherine Harte, PharmD, a PGY2 ambulatory care pharmacy resident at the Rhode Island Hospital in Providence, Rhode Island, discusses the impact of pharmacist management on SGLT2 inhibitors and GLP-1 receptor agonist utilization in patients with type 2 diabetes mellitus.

Although it has clear benefits when monitoring and managing cancer, Feinberg said more widespread use of circulating tumor DNA will take time.

Aimee Banks, PharmD, BCPS, MSCS, clinical pharmacist in the Multiple Sclerosis Clinic at Vanderbilt University Medical Center, discusses new hematology, oncology, and autoimmune therapies in the pipeline that pharmacists should be aware of.

Five-year progression-free survival in the CLL14 trial is approximately 63% in the targeted treatment arm, according to new data.

Medication adherence is critical to control the symptoms of congestive heart failure.

Blinded independent central review analysis also adds confidence to the findings.

The ability to measure GFR would be a significant advancement for clinicians in the United States.

Beth Koselke, PharmD, BCOP, discusses the impact of pharmacist intervention in clinical trial enrollment, specifically in the MYLUNG Consortium.

Nicholas Robert, MD, chief medical officer at Ontada, discusses disparities in biomarker testing and how they are being addresses at ASCO 2022 Annual Meeting.

New results from the ATHENA-MONO trial investigating the use of rucaparib in patients with ovarian cancer show promise.

The trial achieved a complete remission rate of 39.4%, which researcher Michael Dickinson, MBBS, DMedSci, called "remarkable."

Circulating tumor DNA tests could someday replace CT scans for cancer management, according to Bruce Feinberg, DO.

Bruce Feinberg, DO, vice president and chief medical officer at Cardinal Health Specialty Solutions, discussed how a cancer diagnosis and treatment can impact patients’ mental health.

Pharmacy Times spoke with Amila Patel, PharmD, chief clinical officer at Navigating Cancer, to learn about digital health solutions in oncology and what she sees for the future of these solutions.

Kelly McAuliff, PharmD, BCOP, CSP, spoke about research into the impacts of the COVID-19 pandemic on oral oncolytic adherence, particularly for patients with ovarian cancer, prostate cancer, or chronic myelogenous leukemia.

Both patients and providers should recognize the benefits of early referrals to palliative care.

Ahmed Kotb, MD, vice president of US medical affairs, oncology, at AbbVie, discussed new findings from the REFINE trial and what they could mean for patients with myelofibrosis.

With several recent approvals, new CAR T therapies are having significant impacts in multiple myeloma treatment.

Ken Blount, PhD, chief scientific officer at Rebiotix, discusses the investigative treatment RBX2660 and its unique approach to treating Clostridioides difficile infection.

Ogi Kavazovic, co-founder and CEO of House Rx, discusses the company's technology platform and pharmacy service and how it can better enable community oncology pharmacy practices to offer medically integrated dispensing.

Tesh Khullar, co-founder and president of House Rx, discusses how social determinants of health can impact time to treatment initiation.

A panel of experts discuss allergic rhinitis and important counseling points and tactics. They review the current standard of care and identify specific treatment considerations for children, women, elderly, and others.

We're rowing in the same direction as pharmacists, so that what is of interest to a payer, PBMs and pharmacies, according to PQA.

We spoke with Kelly McAuliff, PharmD, BCOP, CSP, to learn about data being presented at the ASCO 2022 Annual Meeting.

Drs Haumschild, Howe, and Gilreath contribute their final perspectives for maximizing care management between providers and patients with myeloproliferative neoplasms.